Maker's Mark Alleges Trademark Dilution by Louisville Dog Treat Company

Bourbon brand Maker's Mark files complaint against WiggleWow Pet Treats, asserting harm to its trademark value

IIPLA News Desk•anonymous access•0 articles left this week

Maker's Mark Alleges Trademark Dilution by Louisville Dog Treat Company

You have reached the guest article limit.

Unlock more of the IIPLA newsroom by signing in with SSO or joining as a member.

Maker's Mark has initiated legal action against Louisville-based WiggleWow Pet Treats, claiming that the pet treat company's use of a similar mark dilutes the value of Maker's Mark's bourbon brand. The dispute centers on trademark rights and potential consumer confusion between the two brands.

Share This Article

Ready-to-post copy includes the article link.

Maker's Mark Alleges Trademark Dilution by Louisville Dog Treat Company Maker's Mark has initiated legal action against Louisville-based WiggleWow Pet Treats, claiming that the pet treat company's use of a similar mark dilutes the value of Maker's Mark's bourbon brand. The dispute centers o... Read the full IIPLA article: https://iipla.org/news/maker-s-mark-alleges-trademark-dilution-by-louisville-dog-treat-company

LinkedIn X Facebook WhatsApp Telegram Email

Related Coverage

Continue in the newsroom

Back to newsroom

PatentsUSA

John A. Squires Appointed Under Secretary of Commerce for Intellectual Property and USPTO Director

John A. Squires serves as the Under Secretary of Commerce for Intellectual Property and Director of the U.S. Patent and Trademark Office (USPTO), overseeing one of the world’s largest IP offices. Bringing extensive experience in intellectual property law, fintech, and regulatory compliance, Squires advises the Preside…

Thursday, May 14, 2026

LitigationUSA

2026 Poised for Surge in U.S. Patent Litigation Amid Pro-Patent Policies and AI Advancements

The year 2026 is projected to witness unprecedented levels of patent litigation in the United States. This surge is attributed to a confluence of factors including supportive pro-patent policies, the integration of advanced artificial intelligence tools in legal processes, and increased availability of litigation fund…

Thursday, May 14, 2026

LitigationUSA

Supreme Court to Weigh Liability of Generic Drug Makers for 'Skinny Label' Patent Infringement in Hikma v. Amarin

On January 16, 2026, the U.S. Supreme Court granted certiorari to review a Federal Circuit ruling in Hikma Pharmaceuticals USA v. Amarin Pharma. The case centers on whether generic drug makers who exclude patented uses from their product labels—so-called 'skinny labels'—can still face patent infringement claims based…

Thursday, May 14, 2026

TrademarksIndia

Supreme Court Affirms Legal Restrictions on Using Trademarks as Loan Security in Canara Bank Case

In a landmark judgment in Canara Bank vs NG Subbaraya Setty, the Supreme Court of India held that the assignment of trademarks as security for outstanding loans is prohibited under existing laws. The ruling emphasizes that trademarks cannot be used as collateral in banking transactions, reinforcing statutory protectio…

Thursday, May 14, 2026

LitigationUSA

Supreme Court Declines to Review Purdue Pharma’s OxyContin Patent Dispute

The U.S. Supreme Court has opted not to take up Purdue Pharma’s appeal concerning patent litigation over its opioid medication OxyContin. This decision means that prior rulings against Purdue in the patent dispute remain in effect, potentially impacting the company’s control over the drug’s intellectual property right…

Thursday, May 14, 2026

PatentsUSA

Federal Circuit Vacates PTAB Ruling on CRISPR-Cas9 Invention, Orders Reconsideration of Patent Priority

The U.S. Court of Appeals for the Federal Circuit has overturned the Patent Trial and Appeal Board’s 2022 decision awarding priority of CRISPR-Cas9 gene editing invention to the Broad Institute. The court ruled that the PTAB applied the wrong legal standard and failed to consider relevant evidence, remanding the case…

Thursday, May 14, 2026